AstraZeneca: Japan approves two new drugs
(CercleFinance.com) - AstraZeneca said on Friday Lynparza received approval for the treatment of advanced ovarian cancer in Japan.
The cancer cell killer - which the group markets in collaboration with US pharma giant Merck - has been approved by the Japanese Ministry of Health, Labour and Welfare for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer who responded to their last platinum-based chemotherapy, the British firm said.
AstraZeneca also said that Japan has approved Fasenra as an add-on treatment for bronchial asthma in patients who continue to experience exacerbations despite treatment with inhaled corticosteroid and other controllers.
This approval follows US FDA approval in November 2017 and European Commission marketing authorisation in January 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The cancer cell killer - which the group markets in collaboration with US pharma giant Merck - has been approved by the Japanese Ministry of Health, Labour and Welfare for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer who responded to their last platinum-based chemotherapy, the British firm said.
AstraZeneca also said that Japan has approved Fasenra as an add-on treatment for bronchial asthma in patients who continue to experience exacerbations despite treatment with inhaled corticosteroid and other controllers.
This approval follows US FDA approval in November 2017 and European Commission marketing authorisation in January 2018.
Copyright (c) 2018 CercleFinance.com. All rights reserved.